The aim of the HemaTMA project is to study the biology, pathology and clinical behavior of hematolymphatic malignancies using various proteogenomics methods.
Funding source
Finnish state research funding, Children's Cancer Foundation Väre
Project
HemaTMA
Tampere University
Clinical Medicine
Duration of project1.1.2019–31.12.2033
Area of focusHealth